BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34954239)

  • 1. Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain).
    Vives N; Binefa G; Vidal C; Milà N; Muñoz R; Guardiola V; Rial O; Garcia M
    Prev Med; 2022 Feb; 155():106929. PubMed ID: 34954239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic.
    Kortlever TL; de Jonge L; Wisse PHA; Seriese I; Otto-Terlouw P; van Leerdam ME; Spaander MCW; Dekker E; Lansdorp-Vogelaar I
    Prev Med; 2021 Oct; 151():106643. PubMed ID: 34217421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population.
    Lee JK; Lam AY; Jensen CD; Marks AR; Badalov J; Layefsky E; Kao K; Ho NJ; Schottinger JE; Ghai NR; Carlson CM; Halm EA; Green B; Li D; Corley DA; Levin TR
    Gastroenterology; 2022 Sep; 163(3):723-731.e6. PubMed ID: 35580655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A delay in the diagnosis of colorectal cancer screened by fecal immunochemical tests during the COVID-19 pandemic: a longitudinal cohort study.
    Ishibashi F; Shida D; Suzuki S; Nagai M; Mochida K; Morishita T
    Int J Colorectal Dis; 2022 Dec; 37(12):2543-2546. PubMed ID: 36383225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study).
    Pilonis ND; Bugajski M; Wieszczy P; Rupinski M; Pisera M; Pawlak E; Regula J; Kaminski MF
    Gastroenterology; 2021 Mar; 160(4):1097-1105. PubMed ID: 33307024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
    van Wifferen F; de Jonge L; Worthington J; Greuter MJE; Lew JB; Nadeau C; van den Puttelaar R; Feletto E; Yong JHE; Lansdorp-Vogelaar I; Canfell K; Coupé VMH;
    J Med Screen; 2022 Jun; 29(2):72-83. PubMed ID: 35100894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of delayed screening invitations on screen-detected and interval cancers in the Dutch colorectal cancer screening programme: individual-level data analysis.
    Toes-Zoutendijk E; de Jonge L; van Iersel CA; Spaander MCW; van Vuuren AJ; van Kemenade F; Ramakers CR; Dekker E; Nagetaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Gut; 2023 Jul; 72(7):1319-1325. PubMed ID: 37076272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of COVID-19 on national program of colorectal cancer screening in Tehran, Iran: a multicenter study.
    Sadeghi A; Asadzadeh Aghdaei H; Khalafi MA; Nazemalhosseini-Mojarad E; Ketabi Moghadam P; Sohrabi MR
    BMC Cancer; 2023 Jul; 23(1):627. PubMed ID: 37407931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the COVID-19 Pandemic on the Diagnosis of Colorectal Cancer within a Population-Based Organized Screening Program.
    Cubiella J; Calderón-Cruz B; Almazán R; Gómez-Amorín Á
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitigating the impact of COVID-19 on colorectal cancer screening: Organized service screening perspectives from the Asia-Pacific region.
    Chiu HM; Su CW; Hsu WF; Jen GH; Hsu CY; Chen SL; Chen HH
    Prev Med; 2021 Oct; 151():106622. PubMed ID: 34044024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal MicroRNA-Based Algorithm Increases Effectiveness of Fecal Immunochemical Test-Based Screening for Colorectal Cancer.
    Duran-Sanchon S; Moreno L; Gómez-Matas J; Augé JM; Serra-Burriel M; Cuatrecasas M; Moreira L; Serradesanferm A; Pozo À; Grau J; Pellisé M; Gironella M; Castells A
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):323-330.e1. PubMed ID: 32113893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the COVID-19 Pandemic on Colorectal Cancer Screening: a Systematic Review.
    Mazidimoradi A; Tiznobaik A; Salehiniya H
    J Gastrointest Cancer; 2022 Sep; 53(3):730-744. PubMed ID: 34406626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nationwide participation in FIT-based colorectal cancer screening in Denmark during the COVID-19 pandemic: An observational study.
    Olesen TB; Jensen H; Møller H; Jensen JW; Andersen B; Rasmussen M
    Elife; 2023 Jan; 12():. PubMed ID: 36695411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the impacts of COVID-19 pandemic on the quality of population-based colorectal cancer screening.
    Jen GH; Yen AM; Hsu CY; Chiu HM; Chen SL; Chen TH
    Prev Med; 2021 Oct; 151():106597. PubMed ID: 34217416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The COVID-19 Pandemic: Identifying Adaptive Solutions for Colorectal Cancer Screening in Underserved Communities.
    Nodora JN; Gupta S; Howard N; Motadel K; Propst T; Rodriguez J; Schultz J; Velasquez S; Castañeda SF; Rabin B; Martínez ME
    J Natl Cancer Inst; 2021 Aug; 113(8):962-968. PubMed ID: 32780851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic.
    de Jonge L; van de Schootbrugge-Vandermeer HJ; Breekveldt ECH; Spaander MCW; van Vuuren HJ; van Kemenade FJ; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    PLoS One; 2022; 17(6):e0270223. PubMed ID: 35749423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of colorectal cancer screening participation in remote northern Canada: A retrospective cohort study.
    Smith HA; Scarffe AD; Brunet N; Champion C; Kandola K; Tessier A; Boushey R; Kuziemsky C
    World J Gastroenterol; 2020 Dec; 26(48):7652-7663. PubMed ID: 33505142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.